Shire Regenerative Medicine Overview
- Year Founded
-
2004
- Status
-
Acquired/Merged
- Employees
-
500
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$750M
Shire Regenerative Medicine General Information
Description
Developer of cell-based regenerative skin substitutes designed for the treatment of chronic wounds. The company's platform integrates living human skin cells within a bioengineered scaffold, manufactured under controlled conditions to support cellular proliferation, biological signaling, extracellular matrix formation, and durable tissue regeneration, with standardized composition, storage, handling characteristics, and consistent clinical performance across applications, enabling healthcare providers to evidence-based management of diabetic foot ulcers.
Contact Information
Corporate Office
- 36 Church Lane
- Westport, CT 06880
- United States
Corporate Office
- 36 Church Lane
- Westport, CT 06880
- United States
Shire Regenerative Medicine Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Merger/Acquisition | 28-Jun-2011 | $750M | Completed | Generating Revenue | ||
| 4. IPO | 18-May-2011 | Cancelled | Generating Revenue | |||
| 3. Later Stage VC (Series C) | 31-May-2007 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series B) | 29-Nov-2005 | $8M | $10.4M | Completed | Generating Revenue | |
| 1. Early Stage VC (Series A) | 01-Oct-2004 | $2.4M | $2.4M | Completed | Product Development |
Shire Regenerative Medicine Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series B | ||||||||
| Series A | 500,561 | $0.001000 | $4.79 | $4.79 | 1x | $4.79 | 4.5% |
Shire Regenerative Medicine Signals
Shire Regenerative Medicine Former Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| CDIB BioScience Venture Management | Venture Capital | Minority | ||
| Canaan Partners | Venture Capital | Minority | ||
| Channel Medical Partners | Venture Capital | Minority | ||
| Red Abbey Venture Partners | Venture Capital | Minority | ||
| Safeguard Scientifics | Growth/Expansion | Minority |
Shire Regenerative Medicine FAQs
-
When was Shire Regenerative Medicine founded?
Shire Regenerative Medicine was founded in 2004.
-
Where is Shire Regenerative Medicine headquartered?
Shire Regenerative Medicine is headquartered in Westport, CT.
-
What is the size of Shire Regenerative Medicine?
Shire Regenerative Medicine has 500 total employees.
-
What industry is Shire Regenerative Medicine in?
Shire Regenerative Medicine’s primary industry is Biotechnology.
-
Is Shire Regenerative Medicine a private or public company?
Shire Regenerative Medicine is a Private company.
-
What is the current valuation of Shire Regenerative Medicine?
The current valuation of Shire Regenerative Medicine is .
-
What is Shire Regenerative Medicine’s current revenue?
The current revenue for Shire Regenerative Medicine is .
-
How much funding has Shire Regenerative Medicine raised over time?
Shire Regenerative Medicine has raised $40.7M.
-
Who are Shire Regenerative Medicine’s investors?
CDIB BioScience Venture Management, Canaan Partners, Channel Medical Partners, Red Abbey Venture Partners, and Safeguard Scientifics are 5 of 7 investors who have invested in Shire Regenerative Medicine.
-
When was Shire Regenerative Medicine acquired?
Shire Regenerative Medicine was acquired on 28-Jun-2011.
-
Who acquired Shire Regenerative Medicine?
Shire Regenerative Medicine was acquired by Shire (Pharmaceuticals).
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process